Cosmo completes Phase II enrolment for rifamycin enema in distal ulcerative colitis trial

  • Cosmo reported completion of patient enrollment in a Phase II trial of rifamycin enema for distal ulcerative colitis and ulcerative proctitis.
  • Topline results have not been presented yet; they are expected in fall 2026.
  • The study will assess whether the locally delivered, gel-forming formulation can improve disease control while limiting systemic exposure.
  • Cosmo enrolled 77 patients across 24 European sites, positioning the program for a potential value inflection point if the readout supports further development.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cosmo Pharmaceuticals NV published the original content used to generate this news brief on May 18, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.